Publication:
Fibroscan detection of fatty liver and liver fibrosis in patients with systemic lupus erythematosus

Simple item page
dc.contributor.authorYILMAZ, YUSUF
dc.contributor.authorBARUTÇU ATAŞ, DİLEK
dc.contributor.authorALİBAZ ÖNER, FATMA
dc.contributor.authorDİRESKENELİ, RAFİ HANER
dc.contributor.authorTUĞLULAR, ZÜBEYDE SERHAN
dc.contributor.authorAŞICIOĞLU, EBRU
dc.contributor.authorVELİOĞLU, ARZU
dc.contributor.authorsYetginoglu O., Atas D., Yilmaz Y., Velioglu A., Arikan H., Alibaz-Oner F., Direskeneli H., Tuglular S., Asicioglu E.
dc.date.accessioned2023-04-12T07:17:43Z
dc.date.available2023-04-12T07:17:43Z
dc.date.issued2022-05-01
dc.description.abstractObjective Although liver dysfunction is not considered the main organ involvement in Systemic Lupus Erythematosus (SLE), the frequency of liver dysfunction or abnormal liver enzyme values may be observed in 50-60% of patients. The aim of this study was to assess fatty liver and liver fibrosis in SLE patients using Fibroscan as well as determine associated factors such as immunosuppressive medications. Methods Sixty SLE patients and 30 healthy controls were included. Patients with HBV, HCV or cirrhosis, malignancy, cardiac disease, or patients on dialysis were excluded. All participants underwent Fibroscan measurements. Results The prevalence of fatty liver disease was similar between SLE patients and healthy controls (21.7 vs 26.7%, p = .597). Liver fibrosis was also similar between the two groups (26.7 vs 10.0%, p = .069). Since the majority of SLE patients were female, we performed a subgroup analysis in female patients (n = 51) and controls (n = 25). Fatty liver disease was similar between female SLE patients and controls (23.5 vs 24.0%, p = .964). However, liver fibrosis in female patients with SLE was increased compared to female controls (29.4 vs 4.0%, p = .011) and was associated with age (Exp (B) 95% CI: 1.083 (1.006-1.166), p = .034) and low-dose cumulative glucocorticoid use (Exp (B) 95% CI: 14.116 (1.213-164.210), p = .034). Conclusion The prevalence of fatty liver was similar between SLE patients and controls, while liver fibrosis was increased in the female patient group as compared to controls. Furthermore, liver fibrosis was associated with age and low dose cumulative glucocorticoid use. Interestingly, fatty liver did not precede liver fibrosis in the majority of cases, contrary to what is observed in the general population. Larger studies are needed to confirm our findings and determine whether immunosuppressive use has any impact on the development of liver fibrosis in SLE patients.
dc.identifier.citationYetginoglu O., Atas D., Yilmaz Y., Velioglu A., Arikan H., Alibaz-Oner F., Direskeneli H., Tuglular S., Asicioglu E., "Fibroscan detection of fatty liver and liver fibrosis in patients with systemic lupus erythematosus.", Lupus, cilt.31, sa.6, ss.723-729, 2022
dc.identifier.doi10.1177/09612033221094708
dc.identifier.endpage729
dc.identifier.issn0961-2033
dc.identifier.issue6
dc.identifier.startpage723
dc.identifier.urihttps://hdl.handle.net/11424/288615
dc.identifier.volume31
dc.language.isoeng
dc.relation.ispartofLupus
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectİmmünoloji ve Romatoloji
dc.subjectMedicine
dc.subjectHealth Sciences
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectImmunology and Rheumatology
dc.subjectROMATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectRHEUMATOLOGY
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectRomatoloji
dc.subjectRheumatology
dc.subjectcorticosteroid
dc.subjectfibroscan
dc.subjecthepatosteatosis
dc.subjectliver fibrosis
dc.subjectsystemic lupus erythematosus
dc.subjectDISEASE
dc.subjectATHEROSCLEROSIS
dc.subjectRISK
dc.titleFibroscan detection of fatty liver and liver fibrosis in patients with systemic lupus erythematosus
dc.typearticle
dspace.entity.typePublication
local.avesis.id92631313-93b8-43e4-b10b-5a72b13f44c8
local.indexed.atWOS
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublication8b32a962-935a-44c5-9970-d30fa5593b4c
relation.isAuthorOfPublication82d26249-dbb5-40e4-962b-63e5334031a5
relation.isAuthorOfPublicatione995a136-8c56-4192-bebe-fe522b567ef1
relation.isAuthorOfPublication07a34d26-21f3-475d-bd36-152d6c659370
relation.isAuthorOfPublication3ea0c6f9-3408-46b6-b382-144ccbf7bc72
relation.isAuthorOfPublication8d7fe885-fe9a-4e61-a77c-587df4c2adbe
relation.isAuthorOfPublicationa7410f0e-0eb4-4b83-ad61-a71dfbee164f
relation.isAuthorOfPublication.latestForDiscovery8b32a962-935a-44c5-9970-d30fa5593b4c

Files

Collections

Research Outputs